Find Payment Providers for Your Peptide Business

Peptide businesses can take card payments when they are matched with a provider whose policy fits their model. Mainstream processors often close peptide accounts, but specialist acquirers routinely underwrite research suppliers, compounding pharmacies, telehealth clinics and skincare brands. What decides the outcome is a clear description of your model and a website that matches it.

Payment challenges in Peptides

  • Most mainstream processors list research chemicals, unapproved drugs or prescription products as prohibited or restricted, so a self-serve account is often closed at the first review of the website.
  • A 'research use only' label does not settle how a product is treated. Regulators and underwriters judge intended use from the whole site: claims, dosing content, imagery and how products are grouped and sold.
  • Pharmacy MCCs 5122 and 5912 are Tier 1 categories in Visa's Integrity Risk Program, and pharmaceutical merchants fall under Mastercard's Registration Program, so the acquirer needs the right scheme registrations before it can board you.
  • The rules are moving. US compounding policy for several popular peptides changed during 2026, and an acquirer's appetite can change with every regulatory step.

What to consider when choosing a PSP or acquirer

Start with the right kind of provider

A general processor that closed your account is not the end of card payments. Peptide businesses are boarded by acquirers with an explicit policy for their model: research supply to laboratories and institutions, prescription dispensing through a pharmacy or telehealth service, cosmetic peptides in skincare or collagen peptides sold as food. Describe your model in those terms from the start, because the MCC, the scheme rules and the documents asked for all follow from it.

Make the website match the model

Underwriters read the live site, not the application. For research supply that means no human-use claims, no dosing or cycle guides, no before-and-after content and no products bundled as body outcomes. In warning letters dated December 2024 and December 2025, the FDA treated online peptide and research-chemical products as unapproved new drugs despite 'research use only' and 'not for human use' labels, because the websites and social media pointed to human use.

An accurate profile is what keeps the account open

Accounts opened under a description that does not match the business tend to be closed at the next website review, often with funds held and a possible listing on Mastercard's MATCH list, which acquirers check before boarding and which keeps a listing for five years. Being boarded for what you really sell, under the right MCC, by a provider that accepts it is what gives a peptide business stable processing.

Prescription peptides: licences and certification first

If peptides are dispensed on prescription, expect to show pharmacy licences for every state or country you ship to, how prescriptions are issued and verified, and who the prescribers are. For MCCs 5122 and 5912, acquirers commonly ask for third-party healthcare merchant certification such as LegitScript, which presents its certification as meeting card brand requirements for those codes.

Know where compounding rules stand

On 15 April 2026 the FDA announced the removal of 12 peptides, including BPC-157 and TB-500, from its Category 2 list of bulk substances that raise significant safety concerns. That did not approve them or place them on Category 1. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of them, BPC-157, TB-500, KPV, MOTs-c, Epitalon and Semax, for the 503A bulks list. The vote is advisory, and formal rulemaking still has to follow, so check the current status before you rely on it.

GLP-1 peptides have their own history

Compounded semaglutide and tirzepatide grew during the US shortages. The FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage on 21 February 2025, and its enforcement discretion for compounding them ended during 2025. Expect underwriters to look closely at any GLP-1 offer, including research-labelled versions of approved or investigational GLP-1 drugs.

What providers assess in your application

Business model
Research supply, prescription dispensing, cosmetic or food. This decides the MCC and which scheme rules apply.
Website and marketing
Claims, dosing content, imagery, social media and affiliate pages, read together as evidence of intended use.
Licences and certification
Pharmacy and prescriber licences where relevant, plus any healthcare merchant certification you already hold.
Customer verification
How you check who buys: institutional or business verification for research supply, valid prescriptions for dispensing.
Products and markets
Which compounds you sell and where you ship, since the legal status of a peptide differs between countries.
Processing history
Chargeback and refund ratios, past account closures and any MATCH listing, all of which change appetite.

Provider suitability differs from business to business: two companies in the same industry can receive opposite answers because of licence, market mix, ticket size or dispute history. We do not state that a provider accepts an industry unless that provider has confirmed it, and no one can guarantee approval.

Check which routes may fit your business

Provider fit in Peptides depends on more than the industry itself: licence, markets, volume and dispute history all change the answer. Answer four questions to start checking your own situation.

Four questions about your business

Industry, company country, customer markets and estimated monthly volume, that is all we need to begin.

Common questions about Peptides payments

Can a peptide business accept card payments?

Yes. Peptide businesses routinely process cards through acquirers whose policy covers their model. The difference from a mainstream processor is that the account is underwritten for what you actually sell, so it is set up to stay open rather than to be closed at the first review. Approval and terms are always the provider's decision.

Are peptides a high-risk category for payment processing?

In most cases, yes. Prescription and pharmacy models sit under MCCs 5122 and 5912, which Visa places in Tier 1 of its Integrity Risk Program, and research-labelled peptides are restricted or prohibited by most mainstream processors. Cosmetic peptides in skincare and collagen peptides sold as food are the exceptions and are usually underwritten like ordinary cosmetics or supplements.

Does a 'research use only' label make a peptide store low risk?

No. The FDA has repeatedly said that such labels do not decide intended use when a website or its social media point to human use. Underwriters apply the same logic: they look at claims, dosing content, product bundles and who the customers are, and judge the business on what the site shows.

Why do peptide sellers lose their payment accounts?

The common reasons are a product category on the processor's prohibited list, a website that contradicts how the business was described at signup, an MCC that does not match the real business, and chargebacks or refunds above what the processor accepts.

Which MCC does a peptide business use?

It depends on the model, and the acquirer assigns it. Prescription dispensing is typically coded as a pharmacy (5912) or under drugs and druggists' sundries (5122). Research supply and cosmetic brands may be coded differently, but only when the website clearly supports that description. Choosing a code to avoid scrutiny is a scheme violation.

Can peptide businesses take cards in the EU and UK?

It depends on how the product is presented. Under EU and UK medicines law, a product presented as treating or preventing disease, or used to restore, correct or modify body functions through a pharmacological, immunological or metabolic action, is a medicinal product and needs authorisation, while peptides in skincare are regulated as cosmetics. Acquirers check that your products and claims fit the rules in each market you sell to.

Do I need LegitScript certification?

Not for every peptide business, but often for pharmacy and telehealth models. For MCCs 5122 and 5912, acquirers commonly ask for third-party healthcare merchant certification such as LegitScript before boarding, and having it in place before you apply avoids a request later in the review.

How does Acquipayer help peptide businesses?

Instead of applying to processor after processor and being closed at review, you describe your model, products, markets, licences, volumes and processing history once in an online application. Your profile is matched with a payment provider whose policy accepts peptide businesses like yours, and your account is prepared with that provider so you can start processing. It is free for merchants, and nothing is shared with a provider until you submit. Approval and final terms are always the provider's decision.

Find payment providers for your Peptides business

Add your business essentials once. Your profile is compared against provider criteria, and nothing is sent until you submit your onboarding pack.

Check my payment options

Nothing is shared with a provider until you submit your onboarding pack. Approval is always the provider's decision.